17 results
Thumbnail

D1.388 - Frequency of Allergic Diseases in Various Age Groups

Thumbnail

D1.389 - How Youth Understand and Manage Risks Associated with Their Food Allergy in Everyday Life

Thumbnail

D1.390 - Long-term safety and efficacy of navenibart in participants with hereditary angioedema (HAE): Initial combined results from ALPHA-STAR and ALPHA-SOLAR

Thumbnail

D1.391 - Comparing Dietary Advancement Therapy for IgE-Mediated Egg Allergy in Primary and Tertiary Care: A Retrospective Review

Thumbnail

D1.392 - Allergic Rhinitis Patients Appear to be at Risk of Lower Quality of Life and Higher Probability of Moderate or Severe Anxiety: Results of an Online Survey in Lithuania

Thumbnail

D1.393 - Building Local Capacity and Improving Access to Specialist Allergist Care for Indigenous Patients in Northern Quebec, Canada

Thumbnail

D1.394 - Characteristics, healthcare provision and expectations of patients with atopic dermatitis as part of the ADCompanion study to evaluate a digital form of care

Thumbnail

D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab

Thumbnail

D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab

Thumbnail

D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis

Thumbnail

D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic

Thumbnail

D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates

Thumbnail

D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab

Thumbnail

D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results

Thumbnail

D1.368 - Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years

Thumbnail

D1.369 - Characteristics of patients with severe asthma undergoing biological treatment at a reference center

Thumbnail

D1.371 - Dupilumab for the treatment of refractory severe chronic spontaneous urticaria